Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Effective anti-fibrotic therapeutic solutions are unavailable so far. The heat shock protein 90 (HSP90) exerts deleterious effects in some fibrotic diseases. S-nitrosylation (SNO) of HSP90 affects its own function, however, little is known about its role in pathological stress. Here, we investigated the effect of SNO-HSP90 on cardiac fibrosis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>SNO-HSP90 level was measured by biotin-switch. SNO sites were identified through mass spectrometry. S-nitrosylation site-mutated plasmids or adeno-associated virus, gene deletion and pharmacological antagonists were used to identify the contribution of SNO-HSP90 in myocardial fibrosis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>SNO-HSP90 level was positively correlated with fibrosis marker expression in hearts from patients and significantly higher in fibrotic hearts from spontaneously hypertensive rats and mice subjected to transverse aortic constriction, as well as in angiotensin II- or isoproterenol-treated neonatal rat cardiac fibroblasts. S-nitrosylated site of HSP90 at cysteine 589 was identified. Inhibition of SNO-HSP90 by Cys589 mutation reduced fibrosis in angiotensin II- or isoproterenol-treated cardiac fibroblasts. Administration of recombinant adeno-associated virus of Cys589 mutation improved heart function and alleviated fibrosis in transverse aortic constriction mice. Mechanismly, SNO-HSP90 stimulated transforming growth factor-β type II receptor (TGFβ RII) binding to HSP90 in response to fibrotic stimuli, subsequently increased phosphorylation and nuclear translocation of SMAD3. Additionally, inducible nitric oxide synthase (<i>iNOS</i>) deficiency or iNOS inhibitor, 1400W, reduced SNO-HSP90 level and the activation of TGFβ/SMAD3 signaling pathway. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and Implications</h3><p>We demonstrate that genetic or pharmacological inhibition of SNO-HSP90 mitigates fibrosis through blocking TGFβ/SMAD3 signaling pathway, providing a potential therapy for cardiac remodeling.</p></section>

Study on the mechanism of OSM participating in myocardial fibrosis by inhibiting TGFβ-induced EndMT of cardiac microvascular endothelial cells through SPARC/SMAD signaling

Suppression of SMOC2 alleviates myocardial fibrosis via the ILK/p38 pathway

Endothelial Klf2-Foxp1-TGF signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling

OSMR Deficiency Aggravates Pressure Overload-Induced Cardiac Hypertrophy by Modulating Macrophages and OSM/LIFR/STAT3 Signalling.

Inhibitory Effects of Oxymatrine on TGF-β1-induced Proliferation and Abnormal Differentiation in Rat Cardiac Fibroblasts Via the P38mapk and ERK1/2 Signaling Pathways

Oncostatin M-Enriched Small Extracellular Vesicles Derived from Mesenchymal Stem Cells Prevent Isoproterenol-Induced Fibrosis and Enhance Angiogenesis

Si-Miao-Yong-An Decoction attenuates isoprenaline-induced myocardial fibrosis in AMPK-driven Akt/mTOR and TGF-β/SMAD3 pathways

Mtorc1 is a Key Regulator That Mediates OGD‑ and TGFβ1‑induced Myofibroblast Transformation and Chondroitin‑4‑sulfate Expression in Cardiac Fibroblasts

Oncostatin M Promotes Infarct Repair and Improves Cardiac Function after Myocardial Infarction.

Inhibition of HSP90 S‐nitrosylation alleviates cardiac fibrosis via TGFβ/SMAD3 signalling pathway

Oncostatin M/Oncostatin M Receptor Signal Induces Radiation-Induced Heart Fibrosis by Regulating SMAD4 in Fibroblast.

OSM Mitigates Post-Infarction Cardiac Remodeling and Dysfunction by Up-Regulating Autophagy Through Mst1 Suppression

Protective Effect of TGF-β-Smads Signal-Based Oxymatrine on Myocardial Fibrosis Induced by Acute Myocardial Infarction in Rats

A1304 Osteoglycin Attenuates Cardiac Fibrosis by Suppressing Cardiac myofibroblast proliferation and migration throughAntagonizing LPA3/MMP2/EGFR signalling

OS 36-06 OSTEOGLYCIN INHIBITS HYPERTENSIVE CARDIAC FIBROSIS THOUGH SUPPRESSION OF EGFR SIGNALING

Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling

Inhibition of Osteopontin Reduce the Cardiac Myofibrosis in Dilated Cardiomyopathy Via Focal Adhesion Kinase Mediated Signaling Pathway.

Osteoglycin Attenuates Cardiac Fibrosis by Suppressing Cardiac myofibroblast proliferation and migration throughAntagonizing LPA3/MMP2/EGFR signaling.

Pharmacological Inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis in Mice Cardiac Fibroblast and Post-Myocardial-Infarction Models

Mir-145 Attenuates Cardiac Fibrosis Through the AKT/GSK-3/-catenin Signaling Pathway by Directly Targeting SOX9 in Fibroblasts

The role of astragaloside IV in extracellular matrix remodeling in fibrotic heart disease: Regulation of TRPM7-dependent macrophage function